Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
Status:
Terminated
Trial end date:
2019-09-10
Target enrollment:
Participant gender:
Summary
The goal of this current study is to prospectively evaluate the influence of a single
subconjunctival aflibercept injection on the regression of corneal neovascularization. Twenty
patients with corneal neovascularization who are candidates for anti VEGF treatment (by the
discretion of a corneal specialist) will be included in this study. The patients will be
treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single
quarter of the conjunctiva, near the limbus in a proximity to the area of pathological
neovascularization. Regression of neovascularization will be documented.